Magdalena Kegel,  —

Removing a protein involved in neuroinflammation is beneficial in early stages of Alzheimer’s disease in mice. However, in late disease stages of the disease, this action has the opposite effect, according to an animal study that helps explain contradicting results observed in earlier research. The findings highlight the role of neuroinflammation…

Trials of deep brain stimulation for Alzheimer’s disease bring with them unique ethical challenges that need to be addressed because these studies are progressing, researchers argue in a recent review article. The trio behind the review — researchers from the University of Pennsylvania — not only raised points for concern, but also provided potential…

Researchers believe that processes that can be used to control immune reactions toward a virus may also be used to prevent neurodegeneration in conditions such as Alzheimer’s disease. To achieve this, researchers blocked the protein PLSCR1 in the brain — a move that prevented immune cells called microglia from attacking…

Selonterra researchers have discovered that the APOE4 gene impacts Alzheimer’s disease (AD) mechanisms in an entirely different way than previously believed. The mutation does not change the behavior of the protein itself, but triggers the activation of nearby genes, which may contribute to Alzheimer’s. The study,…

A group of patients with inherited forms of Alzheimer’s disease was found to have extremely high brain-aluminum levels, leading researchers to suggest there might be a link between genetic vulnerability to the condition and a higher susceptibility to accumulate aluminum in the brain. “Aluminium in brain tissue in familial…

As the disappointment over the failure of solanezumab begins to wane, George Vradenburg, co-founder and chairman of UsAgainstAlzheimer’s, seeks to address the efforts needed to continue research and clinical development for Alzheimer’s disease. Despite the inability of Eli Lilly to bring the goods to the table, Vradenburg applauded Lilly’s…

Genervon Biopharmaceuticals recently shared a previously confidential list of 84 genes linked to Alzheimer’s disease which are modulated by their investigational treatment GM6. The move to make the list public was based on a wish to encourage more neurological scientists to investigate broader, multi-target approaches to treat diseases…

A change in the shape of a protein, rather than its size, is the driving force in small protein aggregates morphing into the insoluble structures present in the brains of Alzheimer’s patients — a process known as nucleation, according to a study. Because the aggregates, known as amyloid-beta oligomers, are…

Researchers have used a novel approach to identify changes in painting patterns that could signal an artist is developing Alzheimer’s disease or another neurodegenerative condition before symptoms show. The team used fractal analysis to look at seven painters’ “artistic fingerprints” over time. Because the changes may occur before cognitive impairment shows…

Researchers have discovered that amyloid-beta — the protein that builds in the brain of Alzheimer’s disease patients — has different structures when it accumulates around blood vessels and neurons. Although the researchers could not conclude how these differences impact the disease, they believe that amyloid buildup around blood vessels differs in…